Fatima Cardoso/myoncologia.pt
Jan 23, 2025, 13:56
2 Neoadjuvant chemo-IO trials for high-risk ER+ BC
Paolo Tarantino, Advanced research fellow at Dana-Farber Cancer Institute, shared an article by Fatima Cardoso on X:
“Simultaneous Nature Medicine publications of 2 neoadjuvant chemo-IO trials for high-risk ER+ BC: KN-756 & CM-7FL.
Both found a striking improvement in pCR rate with IO, with larger Δ if PD-L1+ or low ER.
Waiting for EFS data, which will most likely impact practice.”
Pembrolizumab and chemotherapy in high-risk, early-stage, ER+/HER2− breast cancer: a randomized phase 3 trial.
Authors: Fatima Cardoso, et al.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Jan 23, 2025, 13:56
Jan 23, 2025, 13:45
Jan 23, 2025, 13:39
Jan 23, 2025, 13:37
Jan 23, 2025, 13:35
Jan 23, 2025, 13:24
Jan 23, 2025, 13:23